Development of an Imaging Technique for Boron Neutron Capture Therapy
Open Access
Abstract
The development of 4-10B-borono-2-18F-fluoro-L-phenylalanine (18FBPA) for use in positron emission tomography (PET) has contributed to the progress of boron neutron capture therapy (BNCT). 18FBPA has shown similar pharmacokinetics and distribution to 4-10B-borono-L-phenylalanine (BPA) under various conditions in many animal studies. 18FBPA PET is useful for treatment indication. A higher 18FBPA accumulation ratio of the tumor to the surrounding normal tissue (T/N ratio) indicates that a superior treatment effect is expected. In clinical settings, a T/N ratio of higher than 2.5 or 3 is often used for patient selection. Moreover, 18FBPA PET is useful for predicting the 10B concentration delivered to the tumor and surrounding normal tissues, enabling high-precision treatment planning. Precise dose prediction using 18FBPA PET data has greatly improved the treatment accuracy of BNCT. However, the methodology used for the data analysis of 18FBPA PET findings varies; thus, data should be evaluated using a consistent methodology so as to be more reliable. In addition to PET applications, the development of 18FBPA as a contrast agent for magnetic resonance imaging that combines gadolinium and 10B is also in progress.Keywords
This publication has 41 references indexed in Scilit:
- Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head-and-Neck Cancer: Final Analysis of a Phase I/II TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- BNCT for locally recurrent head and neck cancer: Preliminary clinical experience from a phase I/II trial at Tsing Hua Open-Pool ReactorApplied Radiation and Isotopes, 2011
- 1H and 10B NMR and MRI investigation of boron- and gadolinium–boron compounds in boron neutron capture therapyApplied Radiation and Isotopes, 2011
- The status of Tsukuba BNCT trial: BPA-based boron neutron capture therapy combined with X-ray irradiationApplied Radiation and Isotopes, 2011
- MRI‐Guided Neutron Capture Therapy by Use of a Dual Gadolinium/Boron Agent Targeted at Tumour Cells through Upregulated Low‐Density Lipoprotein TransportersChemistry – A European Journal, 2011
- PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral gliomaApplied Radiation and Isotopes, 2009
- Synthesis of Gd(III)-C-palmitamidomethyl-C′-DOTAMA-C6-o-carborane: a new dual agent for innovative MRI/BNCT applicationsOrganic & Biomolecular Chemistry, 2008
- 4-Borono-2-[18F]fluoro-d,l-phenylalanine: a possible tracer for melanoma diagnosis with PETInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1992
- 4-Borono-2-[18F]fluoro-d,l-phenylalanine as a target compound for boron neutron capture therapy: Tumor imaging potential with positron emission tomographyInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1991
- Synthesis and radiation dosimetry of 4-borono-2-[18F]fluoro-d,l-phenylalanine: A target compound for PET and boron neutron capture therapyInternational Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, 1991